Product Center
Products Center
Jiuhua Huayuan Pharmaceutical makes further progress in the 2023 China Pharmaceutical Industry Top 100 list
Release time:
2024-06-12 00:00
Source:
On June 25th, the highly anticipated "2023 China Pharmaceutical Industry Top 100 Series List" was officially announced at the Misi Conference · Medical and Health Industry Symbiosis Conference held grandly in Huzhou, Zhejiang. Jiuhua Huayuan Pharmaceutical stood out in this selection, ranking 86th on the TOP100 list of Chinese traditional medicine enterprises, up two places from last year, demonstrating its steady growth momentum.
At the same time, the conference released the "China Pharmaceutical · Brand List" and the star product of Jiuhua Huayuan Pharmaceutical, Baimeixing ® Bai Rui particles are prominently listed. In the prevention and treatment of COVID-19, influenza, mycoplasma pneumonia in children and other diseases over the years, Bailui Granule has played a significant therapeutic role, which is the value of brand strength.
In 2023, Jiuhua Huayuan Pharmaceutical not only consolidated Baimeixing ® The market position of Bairui Granules' core products has also increased the research and promotion efforts of new products. Its flagship product, ParknShop ® Zhenyuan tablets won the bid for centralized procurement with significant price advantages and quickly entered the clinical market, providing better treatment options for patients with cardiovascular and cerebrovascular diseases. At the same time, the company's exclusive products, Yanshuikang Granules and Yuye Jinhua Qingre Tablets, have also occupied important positions in the pediatric and respiratory markets.
Jiuhua Huayuan Pharmaceutical's strength in research and development cannot be underestimated. As of now, the company has more than 30 products under development and holds 53 national patents. The postdoctoral research workstation, provincial enterprise technology center, and other technological innovation platforms provide a solid foundation for the company to introduce, digest, absorb, and innovate advanced technologies at home and abroad. In order to further enhance its competitiveness, Jiuhua Huayuan Pharmaceutical has continued to increase investment in research and development, continuously introducing and cultivating high-end talents, and building a professional R&D team. At the same time, the company actively establishes cooperative relationships with well-known domestic and foreign research institutions and universities to jointly carry out new drug research and technological innovation, injecting a continuous stream of power into the company's sustainable development.
In the future, Jiuhua Huayuan Pharmaceutical will continue to adhere to the development concept of "steady loyalty and innovative mileage", continuously improving its research and development strength and market competitiveness. The company will continue to increase investment, expand into new business areas, and promote the company's development towards higher levels, wider fields, and deeper levels. At the same time, Jiuhua Huayuan Pharmaceutical will actively fulfill its social responsibility and contribute more to the cause of human health.
